This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BLUE bluebird bio (BLUE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About bluebird bio Stock (NASDAQ:BLUE) Get bluebird bio alerts:Sign Up Key Stats Today's Range$4.97▼$4.9750-Day Range$3.29▼$5.0052-Week Range$3.20▼$5.03VolumeN/AAverage Volume807,956 shsMarket Capitalization$48.67 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts. Read More Receive BLUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BLUE Stock News HeadlinesBLUE OWL CAPITAL INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Blue Owl Capital Inc.'s Directors and Officers for Breach of Fiduciary Duties – OWLMarch 3, 2026 | businesswire.comBLUE MOON METALS TO BEGIN TRADING ON NASDAQ UNDER BMM AND APPOINTS PETER MADSEN TO THE BOARD OF DIRECTORSJanuary 23, 2026 | prnewswire.comThe system holding the dollar together is gone…Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every country on Earth to hold U.S. dollars to buy oil. Since then, Saudi Arabia has signed a $7 billion currency swap with China, begun settling oil in digital yuan, and joined China's cross-border payment system, mBridge. With 10-year Treasury yields pushing toward the 4.4% danger line and global dollar demand in retreat, gold is being repriced. There's one asset that still trades at a steep discount to gold's current price - a rare opportunity to leverage the metal's continued rise.May 14 at 1:00 AM | Golden Portfolio (Ad)Zag Bio emerges with plans to treat immune disease by targeting the thymusOctober 28, 2025 | yahoo.comBluebird bio flies to pastures new with Genetix rebrandingSeptember 19, 2025 | finance.yahoo.combluebird bio Rebrands as Genetix Biotherapeutics, Returning to Its Foundational RootsSeptember 18, 2025 | finance.yahoo.combluebird bio Rebrands as Genetix Biotherapeutics, Returning to Its Foundational RootsSeptember 18, 2025 | businesswire.comPetri Dish: ProFound’s Novartis deal worth $750M, Dyne secures debtJuly 3, 2025 | bizjournals.comSee More Headlines BLUE Stock Analysis - Frequently Asked Questions How were bluebird bio's earnings last quarter? bluebird bio, Inc. (NASDAQ:BLUE) issued its quarterly earnings results on Tuesday, November, 7th. The biotechnology company reported ($13.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($13.80) by $0.60. The company's revenue was up 17364.8% compared to the same quarter last year. Read the conference call transcript. When did bluebird bio's stock split? bluebird bio shares reverse split before market open on Friday, December 13th 2024.The 1-20 reverse split was announced on Wednesday, December 4th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did bluebird bio IPO? bluebird bio (BLUE) raised $89 million in an initial public offering on Wednesday, June 19th 2013. The company issued 5,941,176 shares at a price of $14.00-$16.00 per share. What other stocks do shareholders of bluebird bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that bluebird bio investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT (). Company Calendar Last Earnings11/07/2023Today5/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (38m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 BLUE's financial health is in the Red zone, according to TradeSmith. BLUE has been in this zone for over 38 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BLUE CIK1293971 Webwww.bluebirdbio.com Phone(339) 499-9300FaxN/AEmployees520Year Founded1992Profitability EPS (Trailing Twelve Months)($41.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$211.91 million Net Margins-565.74% Pretax Margin-551.41% Return on Equity-322.46% Return on Assets-53.17% Debt Debt-to-Equity Ratio0.37 Current Ratio0.51 Quick Ratio0.33 Sales & Book Value Annual Sales$103.95 million Price / Sales0.47 Cash FlowN/A Price / Cash FlowN/A Book Value$35.59 per share Price / Book0.14Miscellaneous Outstanding Shares9,792,000Free Float9,586,000Market Cap$48.67 million OptionableOptionable Beta0.27 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free Report This page (NASDAQ:BLUE) was last updated on 5/14/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredThe system holding the dollar together is gone…Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...Golden Portfolio | SponsoredMillionaire warns: Move your money before May 15Larry Benedict - the trader who generated $274 million in client profits and beat the S&P 500 by 18 times in 2...Brownstone Research | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredWhat Expenses Can Be Deducted From Capital Gains Tax This Year?Capital gains taxes can quietly erode investment returns - but the tax code offers legitimate ways to potentia...SmartAsset | SponsoredTrump Just Named His Secret AI Project. It's Called "Golden Dawn."Behind a hidden government lab in Tennessee, 40,000 scientists are reportedly finishing work on an AI system d...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bluebird bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share bluebird bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BLUE Stock Alerts